Stock Track | Biogen Soars 5% Intraday as Q2 Earnings and Revenue Beat, Growth Portfolio Drives Outlook Raise

Stock Track

Jul 29

Shares of Biogen (BIIB) surged 5.03% intraday on Wednesday after the biotechnology company reported second-quarter financial results that significantly exceeded Wall Street expectations, fueled by strong demand for its newer drugs.

The company posted adjusted earnings of $3.60 per share, well above the analyst consensus estimate of $2.95 per share. Quarterly revenue rose 3.4% to $2.74 billion, beating the $2.46 billion forecast. The outperformance was driven by Biogen's growth portfolio, which includes rare disease medicines and the Alzheimer's drug Leqembi, generating nearly $1.1 billion in revenue—up 24% from the prior year and outpacing its legacy multiple sclerosis franchise for the second time in company history.

Adding to investor optimism, Biogen raised its full-year revenue guidance, now expecting a mid-single-digit percentage increase, a reversal from its prior forecast of a decline. The company also received an analyst price target boost from Barclays, which lifted its target to $200 from $185, reflecting confidence in the evolving pipeline and acquisition strategy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1165330770"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165330770\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165330770?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165330770","market":"us","top_or_hot":-1,"title":"Stock Track | Biogen Soars 5% Intraday as Q2 Earnings and Revenue Beat, Growth Portfolio Drives Outlook Raise","media":"Stock Track","content":"<p>Shares of Biogen (BIIB) surged 5.03% intraday on Wednesday after the biotechnology company reported second-quarter financial results that significantly exceeded Wall Street expectations, fueled by strong demand for its newer drugs.</p>\n<p>The company posted adjusted earnings of $3.60 per share, well above the analyst consensus estimate of $2.95 per share. Quarterly revenue rose 3.4% to $2.74 billion, beating the $2.46 billion forecast. The outperformance was driven by Biogen's growth portfolio, which includes rare disease medicines and the Alzheimer's drug Leqembi, generating nearly $1.1 billion in revenue—up 24% from the prior year and outpacing its legacy multiple sclerosis franchise for the second time in company history.</p>\n<p>Adding to investor optimism, Biogen raised its full-year revenue guidance, now expecting a mid-single-digit percentage increase, a reversal from its prior forecast of a decline. The company also received an analyst price target boost from Barclays, which lifted its target to $200 from $185, reflecting confidence in the evolving pipeline and acquisition strategy.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Biogen Soars 5% Intraday as Q2 Earnings and Revenue Beat, Growth Portfolio Drives Outlook Raise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Biogen Soars 5% Intraday as Q2 Earnings and Revenue Beat, Growth Portfolio Drives Outlook Raise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-29 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Biogen (BIIB) surged 5.03% intraday on Wednesday after the biotechnology company reported second-quarter financial results that significantly exceeded Wall Street expectations, fueled by strong demand for its newer drugs.</p>\n<p>The company posted adjusted earnings of $3.60 per share, well above the analyst consensus estimate of $2.95 per share. Quarterly revenue rose 3.4% to $2.74 billion, beating the $2.46 billion forecast. The outperformance was driven by Biogen's growth portfolio, which includes rare disease medicines and the Alzheimer's drug Leqembi, generating nearly $1.1 billion in revenue—up 24% from the prior year and outpacing its legacy multiple sclerosis franchise for the second time in company history.</p>\n<p>Adding to investor optimism, Biogen raised its full-year revenue guidance, now expecting a mid-single-digit percentage increase, a reversal from its prior forecast of a decline. The company also received an analyst price target boost from Barclays, which lifted its target to $200 from $185, reflecting confidence in the evolving pipeline and acquisition strategy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"","article_id":"1165330770","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165330770","pubTimestamp":1785332734,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Biogen (BIIB) surged 5.03% intraday on Wednesday after the biotechnology company reported second-quarter financial results that significantly exceeded Wall Street expectations, fueled by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"股票跟踪 | Biogen 第二季度盈利和收入超出预期，增长投资组合推动前景上调，盘中飙升 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1},"content_text":"Shares of Biogen (BIIB) surged 5.03% intraday on Wednesday after the biotechnology company reported second-quarter financial results that significantly exceeded Wall Street expectations, fueled by strong demand for its newer drugs.\nThe company posted adjusted earnings of $3.60 per share, well above the analyst consensus estimate of $2.95 per share. Quarterly revenue rose 3.4% to $2.74 billion, beating the $2.46 billion forecast. The outperformance was driven by Biogen's growth portfolio, which includes rare disease medicines and the Alzheimer's drug Leqembi, generating nearly $1.1 billion in revenue—up 24% from the prior year and outpacing its legacy multiple sclerosis franchise for the second time in company history.\nAdding to investor optimism, Biogen raised its full-year revenue guidance, now expecting a mid-single-digit percentage increase, a reversal from its prior forecast of a decline. The company also received an analyst price target boost from Barclays, which lifted its target to $200 from $185, reflecting confidence in the evolving pipeline and acquisition strategy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}